Suppr超能文献

含棕榈酸齐多夫定的固体脂质纳米粒在高压灭菌、储存和冻干后的药物保留率及稳定性

Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving, storage and lyophilization.

作者信息

Heiati H, Tawashi R, Phillips N C

机构信息

Faculté de Pharmacie, Université de Montréal, Québec, Canada.

出版信息

J Microencapsul. 1998 Mar-Apr;15(2):173-84. doi: 10.3109/02652049809006847.

Abstract

Solid lipid nanoparticles (SLNs) were prepared using trilaurine (TL) as the SLN core and phospholipid (PL) as coating. Neutral and negatively charged PLs were used to produce neutral and negatively charged SLNs. An ester prodrug of 3'-azido-3'-deoxythymidine (Zidovudine, AZT), AZT palmitate (AZT-P), was synthesized and incorporated in the SLNs. The stability of SLN formulations containing AZT-P was studied at different temperatures. Drug retention and mean particle diameter of SLNs were determined after autoclaving, during temperature stability testing, and after lyophilization (with or without cryoprotective sugars) and reconstitution. There were no significant changes in the mean diameter and the zeta potential (zeta) of SLNs after autoclaving (121 degrees C for 20 min). The amount of incorporated AZT-P was, however, slightly reduced due to the formation of hydrosoluble AZT. Autoclaved SLNs were stable for a period of 10 weeks at 20 degrees C but an increase in particle size and loss of AZT-P were observed at 4 and 37 degrees C. Trehalose was an effective cryoprotectant for preventing SLN aggregation during lyophilization and subsequent reconstitution. Thermal gravimetric analysis showed that lyophilized preparations contained approximately 1% water. Using appropriate trehalose to lipid ratios, AZT-P retention in the SLNs was 100% after reconstitution. Our results demonstrate that SLNs containing AZT-P can be autoclaved, lyophilized and reconstituted without significant changes in SLN diameter and zeta potential or in the quantity of incorporated prodrug.

摘要

以三月桂精(TL)为固体脂质纳米粒(SLN)核心、磷脂(PL)为包衣制备了SLN。使用中性和带负电荷的PL来制备中性和带负电荷的SLN。合成了3'-叠氮-3'-脱氧胸苷(齐多夫定,AZT)的酯前药AZT棕榈酸酯(AZT-P),并将其载入SLN中。研究了含AZT-P的SLN制剂在不同温度下的稳定性。在高压灭菌后、温度稳定性测试期间、冻干(有无冷冻保护糖)及复溶后,测定了SLN的药物保留率和平均粒径。高压灭菌(121℃,20分钟)后,SLN的平均直径和zeta电位(zeta)没有显著变化。然而,由于水溶性AZT的形成,载入的AZT-P量略有减少。高压灭菌后的SLN在20℃下可稳定10周,但在4℃和37℃下观察到粒径增加和AZT-P损失。海藻糖是冻干及后续复溶过程中防止SLN聚集的有效冷冻保护剂。热重分析表明,冻干制剂含水量约为1%。使用合适的海藻糖与脂质比例,复溶后SLN中AZT-P的保留率为100%。我们的结果表明,含AZT-P的SLN可进行高压灭菌、冻干及复溶,而SLN直径、zeta电位或载入前药的量均无显著变化。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验